Marion Feuilly

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

David Cella, Jennifer L. Beaumont, Stacie Hudgens et al. · Clinical Therapeutics · 2018 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

Daphne T. Adelman, Xuan-Mai Truong Thanh, Marion Feuilly et al. · Advances in Therapy · 2020 · 21 citations · Full text

Medicine, Endocrinology, Oncology +13

Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)

Daniel Orbach, Matthieu Carton, S.K. Khadir et al. · ESMO Open · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Ronald C. Chen, Toni K. Choueiri, Marion Feuilly et al. · Cancer · 2020 · 15 citations · Full text

Medicine, Oncology, Pharmacology +14

Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI

Matthieu Carton, Johanna Peña Del Castillo, Jean-Baptiste Colin et al. · Future Oncology · 2023 · 12 citations · Full text

Medicine, Oncology, Pharmacology +13